The treatment of chronic metabolic acidosis in CKD patients, both pharmacological and nutritional, would seem to attenuate the maladaptive responses of the kidneys by reducing the levels of angiotensin II, aldosterone, endothelin-1 and ammoniagenesis and whilst simultaneously slowing down CKD progression. This evidence concerns the gene EDN1 and chronic kidney disease.